课题基金 / 基金详情

COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)

COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)
DLV、ZDV 和 3TC 作为初始或后续治疗的联合试验（第二部分）
批准号：
6121105
负责人：
PHILIP C JOHNSON
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121105
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy delavirdine genotype human immunodeficiency virus human subject human therapy evaluation lamivudine leukocyte count phenotype reverse transcriptase inhibitors zidovudine

项目摘要

项目成果

PHILIP C JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
这项双盲随机试验的目的是评估使用和不使用非核苷类逆转录酶抑制剂地拉韦定的双重和三联疗法的安全性和耐受性。这些组合将包括DLV、齐多夫定(ZDV)和拉米夫定(3TC)。第一部分比较ZDV的患者和不使用DLV的患者加上新研究HIV+、CD4计数为200-500/mm3、总ZDV经历为0-6个月的患者将被研究。还将对出现的表型和遗传型变化进行评估。这项研究的中期分析显示，三联疗法比其他两种疗法中的任何一种都要好。这项研究于1998年初由dsmb结束。
英文摘要
The aim of this double blind, randomized trial is to evaluate the safety and tolerance of double and triple combination therapies with and without delavirdine, a non-nucleoside reverse transcriptase inhibitor. These combinations will include DLV, zidovudine (ZDV), and lamivudine (3TC). Patients from Part I comparing ZDV with and without DLV plus new study HIV+ patients with CD4 counts of 200-500/mm3 and with 0-6 months total ZDV experience will be studied. Phenotypic and genotypic changes that emerge will also be evaluated. Interim analysis of this study showed the triple combination therapy to be better than either of the other two arms. The study was closed by the DSMB early in 1998.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
海外基金